GlassScriptPhysician profile
Brett Andrew Steinicke
NPI 1689250276
$940.82
in general payments reported to CMS, 2019-2025
25 companies · $764 in 2025
The $764 reported for 2025 was more than what 81% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $177 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $940.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $160.05 | 2024-2025 | Trelegy Ellipta, Bexsero |
| Lilly USA, LLC | $114.90 | 2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $78.97 | 2024-2025 | Farxiga, Airsupra |
| Pfizer INC. | $66.65 | 2025 | |
| Abbvie INC. | $64.66 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $54.48 | 2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.11 | 2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $32.65 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $32.44 | 2024-2025 | |
| Amgen INC. | $29.74 | 2024-2025 | Otezla, Repatha, Otezla |
| Dynavax Technologies Corporation | $25.65 | 2024-2025 | Heplisav-B |
| Seqirus USA INC | $25.61 | 2024 | Flucelvax |
| Sumitomo Pharma America, INC. | $24.88 | 2025 | Gemtesa |
| Lundbeck LLC | $19.49 | 2025 | Rexulti |
| Medtronic, INC. | $18.42 | 2025 | Minimed 780g |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $18.31 | 2024 | |
| Cranial Technologies, INC | $16.14 | 2025 | Doc Band |
| Novo Nordisk INC | $15.84 | 2025 | Ozempic |
| Axsome Therapeutics, INC. | $15.07 | 2025 | Auvelity |
| Astellas Pharma US INC | $14.81 | 2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.75 | 2025 | Xifaxan |
| Corium, LLC | $14.49 | 2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $14.26 | 2025 | Spravato |
| Collegium Pharmaceutical, INC. | $13.83 | 2025 | Jornay Pm |
| Becton, Dickinson and Company | $13.62 | 2025 | Bd Onclarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brett Steinicke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.